WHO WE ARE

Built to scale life-changing gene therapies

We give innovators the best way to scale through rAAV-based gene therapy manufacturing.

Iria, Pediatric Parkinson’s patient

Irai, a Pediatric Parkinson’s patient treated with an innovation manufactured at Viralgen

Powering today’s gene therapies for her tomorrow

As an independently operated subsidiary of AskBio, we provide our clients access to foundational science in applying adeno-associated viruses (AAVs) for therapeutic purposes. That science, when teamed with our best-in-class production capabilities, uniquely positions us to help our clients advance their gene therapies for any indication, from ultra-rare to pathway diseases. No matter the application, our efficient scale-up and its benefits helps enable lower-cost therapies to reach more patients. And to give patients like Irai hope they’ve never had before.

Our Values

Our purpose is simple, but sweeping: To remain the best place in the world to make AAV-based gene therapies. We can only achieve that purpose by adhering to our core corporate values.
Expertise Icon

Expertise

Our focus on AAV gene therapies leverages our historical expertise and our deep understanding of the design, quality, manufacture, and supply of these therapies worldwide.

Trust Icon

Trust

Honesty and transparency build reliable relationships. We play a critical role for our customers and this privilege requires us to be trustworthy and accountable partners.

Empathy Icon

Empathy

People are at the core of our company. Compassion and solidarity guide our approach to understand and meet the needs of all of our stakeholders.

Our Executive Leadership Team

Get to know just some of the 400+ professionals at Viralgen who guide the development of our clients’ most important and ambitious gene therapy manufacturing initiatives.
Jimmy Vanhove
Jimmy Vanhove
Chief Executive Officer
Javier García Cogorro
Javier García Cogorro
Chairman of the Board
César Trigueros, PhD
César Trigueros, PhD
Chief Scientific Officer
Andy Holt
Andy Holt
Executive Vice President, Commercial Development
Kontxi San Juan
Kontxi San Juan
Chief Human Resources
Marta Labayen
Marta Labayen
Chief Financial Officer
Philippe Moullier, MD, PhD
Philippe Moullier, MD, PhD
Senior Advisor
Ana Barbas
Ana Barbas
Head of Strategy and Business Excellence
María Iglesias
María Iglesias
Head of Digital and IT
Darío Sánchez
Darío Sánchez
Head of Engineering
Saulye Sherrell
Saulye Sherrell
Chief Manufacturing Officer
Francisco Diez
Francisco Diez
Director of Quality

Our Partners

Viralgen supplies and provides products for gene therapy research and development with the aim of treating several rare and ultra-rare diseases through Columbus Children’s Foundation and Fundación Columbus. We also collaborate with commercial partners to support early-stage research initiatives for treatments aimed at rare diseases (including, for example, drug-resistant focal epilepsy, Spastic Paraplegia 50, and Charcot-Marie-Tooth disease type 4J).

partner_logo_1 1
partner_logo_2 1

Foundation Partners

AADC

Aromatic L - Amino Acid Decarboxylase Deficiency

NPC

Niermann Pick type C

NPA

Niermann Pick type A

SPG50

Spastic paraplegia 50

DMD Exon 1

Duchenne Muscular Dystrophy Exon 1 deletion

MPS IIIC

Mucopolysaccharidosis type IIIC

Strategic Partners

CombiGene

UCL Technology Fund

Elpida

Our past powers our present

Here, each new day holds in it the opportunity to mark a critical milestone in the development of gene therapies for pathway and rare genetic diseases. We know that to be true because we’ve witnessed it firsthand since our founding in 2017.

'24

We opened Module 2 and launch our MSAT laboratories to support process development and characterization.

'22

Our new facility receives cGMP certification for the manufacture of human medicinal products, investigational medicinal products and sterile or biological active substances by the AEMPS, a part of the EMA network. The company now operates 7 state-of-the-art, single-use suites that have up to 2,000 liters of manufacturing capacity. 

'21

The first phase of Viralgen’s expansion is completed for Module 1. It increases capacity fivefold and allows coverage of projects from the preclinical phase to commercial production.

'20

The second and third suites are accredited. The construction phase of Viralgen’s second facility begins, enabling industrial-scale manufacturing. In October, AskBio is acquired by Bayer.

'19

In July, the first clinical suites are accredited by the Spanish Agency of Medicines cGMP production and marketing.

'18

Facility construction concludes in September and the process of technology transfer and scale up begins.

'17

In September, Viralgen launches two laboratories in the Gipuzkoa Science and Technology Park.

'15

The company’s eventual founders, AskBio and ColumbusVP, meet for the first time to pave the way for the future of gene therapy manufacturing.

home_1001-small 1

Where we go from here

Want to know more about Viralgen or how we can help you get your gene therapy to more patients in a better way? Just contact us to get a conversation going.

Please review the following rules: